Updated safety data of 36 patients treated with FT819 across three regimens and four autoimmune disease indications with no dose-limiting toxicities continues to be favorable 100% (3 of 3) of extrarenal lupus patients treated with FT819 without the use of conditioning chemotherapy experienced measurable responses with two patients achieving the Definition of Remission in Systemic Lupus Erythematosus (DORIS) and the third achieving Lupus Low Disease Activity State (LLDAS) First patient treated with two doses of FT819 achieved a significant reduction of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) by 8 points at Month 1, achieving LLDAS by Month 2, which was sustained at Month 3 New preclinical data show FT839 eliminates a broad spectrum of activated immune cells in models of rheumatoid arthritis supporting immune cell reset in multicellular disease; COMPLETE™ Phase 1/2 basket trial open for enrollment SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that updated clinical data for FT819, together with translational and patient-perspective data, as well as preclinical data for FT839, are being presented in four presentations at the American College of Rheumatology (ACR) Convergence 2026, held November 6–11 in Orlando, Florida. "Our recent clinical data presented at ACR continues to show that FT819 can be delivered in a safe and effective manner that fits into routine rheumatology care," said Bob Valamehr, Ph.D.